Cardlytics Inc (CDLX) Performance and Fundamentals Dashboard tells a completely different story

With 0.91 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.67 million shares. The 52-week range on CDLX shows that it touched its highest point at $20.52 and its lowest point at $2.60 during that stretch. It currently has a 1-year price target of $17.00. Beta for the stock currently stands at 1.44.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDLX was down-trending over the past week, with a drop of -9.06%, but this was up by 74.43% over a month. Three-month performance surged to 54.98% while six-month performance fell -11.88%. The stock gained 407.37% in the past year, while it has gained 57.00% so far this year. A look at the trailing 12-month EPS for CDLX yields -3.49 with Next year EPS estimates of -0.89. For the next quarter, that number is -0.47. This implies an EPS growth rate of 65.04% for this year and 31.01% for next year. EPS is expected to grow by 44.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -5.75%.

Float and Shares Shorts:

At present, 44.11 million CDLX shares are outstanding with a float of 40.76 million shares on hand for trading. On Mar 15, 2024, short shares totaled 4.48 million, which was 10.16% higher than short shares on Feb 15, 2024. In addition to CDTX as the firm’s Cidara Therapeutics, Inc., CLX serves as its Clorox Company (The).

Institutional Ownership:

Through their ownership of 68.71% of CDLX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDLX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, CDLX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CDLX currently yields $0.00. In the past year, CDLX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CDLX has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.